VWM
ONCT

Vigilare Wealth Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Vigilare Wealth Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,466
Closed -$112K – 183
2021
Q4 		$112K Sell
2,466
-707
-22% -$47.6K 0.07% 174
2021
Q3 		$265K Buy
3,173
+546
+21% +$45.2K 0.16% 159
2021
Q2 		$250K Buy
2,627
+1,051
+67% +$125K 0.15% 171
2021
Q1 		$262K Buy
1,576
+451
+40% +$59.6K 0.19% 149
2020
Q4 		$110K Buy
+1,125
New +$71.2K 0.1% 146

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vigilare Wealth Management's ONCT Position: Q1 2022 in Review

Vigilare Wealth Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2022, closing a stake of 2,466 shares — an estimated $112K sold.

Vigilare Wealth Management first reported a position in ONCT in Q4 2020 and held it in 5 quarters. The position peaked at $265K in Q3 2021. 78 funds tracked by Wall St. Rank hold ONCT as of Q1 2022.

  • Vigilare Wealth Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Vigilare Wealth Management sold 2,466 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $112K.
  • Vigilare Wealth Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Vigilare Wealth Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $265K in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Vigilare Wealth Management's 13F filing for Q1 2022, filed 6 Apr 2022.